The FDA has reaffirmed its position that elevated LDL is a risk factor for heart attack, stroke, and sudden death, among other cardiovascular diseases, and that reducing LDL levels lowers the risk of these diseases.
The FDA has accepted an investigational new drug (IND) application from Medarex, Inc., for MDX-1203, the company’s first antibody-drug conjugate (ADC). The ADC is made of a potent cytotoxic prodrug chemically linked with an anti-CD70 antibody.
The Glucocard 01-mini Blood Glucose Monitoring System from Arkray USA, Inc., of Minneapolis, the only such system that features interchangeable faceplates so users can personalize the look of their monitor, has received marketing clearance.
Gelnique (oxybutynin chloride) Gel 10%, the first and only topical gel for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, has received FDA approval.
Surgery for kidney cancer may help resolve concomitant arterial hypertension, according to a study.
Like immunocompromised individuals, CKD patients are especially vulnerable to foodborne illnesses.
About two years ago, having recognized that the prostate-specific antigen (PSA) cutoff level of 4.0 ng/mL did not always assist in accurately categorizing a man’s risk for prostate cancer, we began to eliminate this—or any—artificial cutoff defining a “normal” PSA value.
This article is the second in a series on hyperphosphatemia management in CKD patients.
MARCO ISLAND, Fla.—Domino paired donation (DPD) and never-ending altruistic donor (NEAD) chains are part of a new spectrum of options for patients with end-stage renal disease (ESRD) who need renal transplants but have incompatible donors.
MARCO ISLAND, Fla.—The transplant community may want to rethink the importance of HLA mismatches when considering live donor kidney transplants, according to new data presented here at the American Society of Transplant Surgeons (ASTS) 9th Annual State of the Art Winter Symposium.
